Sacubitril/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sacubitril/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction
Authors
Keywords
-
Journal
European Journal of Pharmacology
Volume -, Issue -, Pages 176170
Publisher
Elsevier BV
Online
2023-11-07
DOI
10.1016/j.ejphar.2023.176170
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Heart failure with preserved ejection fraction and atrial fibrillation: recent advances and open questions
- (2023) Laurent Fauchier et al. BMC Medicine
- Heart Failure With Preserved Ejection Fraction
- (2023) Margaret M. Redfield et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF
- (2022) Alexander Peikert et al. EUROPEAN JOURNAL OF HEART FAILURE
- Blocking VCAM-1 Prevents Angiotensin II-Induced Hypertension and Vascular Remodeling in Mice
- (2022) Liangqingqing Yin et al. Frontiers in Pharmacology
- Inflammatory Markers and Risk of Heart Failure With Reduced to Preserved Ejection Fraction
- (2022) Zainab Albar et al. AMERICAN JOURNAL OF CARDIOLOGY
- Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics
- (2022) Miyesaier Abudureyimu et al. Journal of Molecular Cell Biology
- Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
- (2022) Magnus O. Wijkman et al. Cardiovascular Diabetology
- Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction
- (2022) Ruoyu Jia et al. BIOMEDICINE & PHARMACOTHERAPY
- Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial
- (2022) Safia Chatur et al. EUROPEAN JOURNAL OF HEART FAILURE
- Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction
- (2022) Josephine Harrington et al. JAMA Cardiology
- Health‐related quality of life outcomes in PARAGON‐HF
- (2022) Alvin Chandra et al. EUROPEAN JOURNAL OF HEART FAILURE
- Blocking VCAM-1 ameliorates hypertensive cardiac remodeling by impeding macrophage infiltration
- (2022) Ze-Yang Qiu et al. Frontiers in Pharmacology
- Cellular and molecular pathobiology of heart failure with preserved ejection fraction
- (2021) Sumita Mishra et al. Nature Reviews Cardiology
- Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats
- (2021) Wenchao Zhang et al. Frontiers in Pharmacology
- Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness
- (2021) Annayya R. Aroor et al. Cardiovascular Diabetology
- From Systemic Inflammation to Myocardial Fibrosis
- (2021) Walter J. Paulus et al. CIRCULATION RESEARCH
- Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF
- (2021) Antje Schauer et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction
- (2021) Alice M Jackson et al. EUROPEAN HEART JOURNAL
- Heart failure with mid-range or mildly reduced ejection fraction
- (2021) Gianluigi Savarese et al. Nature Reviews Cardiology
- Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF
- (2021) Mauro Gori et al. JACC-Heart Failure
- Sacubitril/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation
- (2020) Lu-yi-fei Li et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction
- (2020) Jonathan W. Cunningham et al. JACC-Heart Failure
- Heart Failure with Preserved Ejection Fraction: Insights into Diagnosis and Pathophysiology
- (2020) Sherif F Nagueh CARDIOVASCULAR RESEARCH
- Metabolic Inflammation in Heart Failure with Preserved Ejection Fraction
- (2020) Gabriele G Schiattarella et al. CARDIOVASCULAR RESEARCH
- Prognostic impacts of dynamic cardiac structural changes in heart failure patients with preserved left ventricular ejection fraction
- (2020) Shinsuke Yamanaka et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF
- (2020) Jonathan W. Cunningham et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure with Preserved Ejection Fraction:Results from the PROMIS-HFpEF Study
- (2020) Sandra Sanders-van Wijk et al. CIRCULATION
- Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF
- (2020) Karola S. Jering et al. JACC-Heart Failure
- Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology
- (2019) Rudolf A. de Boer et al. EUROPEAN JOURNAL OF HEART FAILURE
- Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment
- (2019) Heidi Harjunpää et al. Frontiers in Immunology
- Blockade of intercellular adhesion molecule-1 prevents angiotensin II-induced hypertension and vascular dysfunction
- (2019) Ping-Ping Lang et al. LABORATORY INVESTIGATION
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
- (2019) Scott D. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacological blockage of ICAM-1 improves angiotensin II-induced cardiac remodeling by inhibiting adhesion of LFA-1+ monocytes
- (2019) Qiu-Yue Lin et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared with Valsartan in HFpEF
- (2019) Muthiah Vaduganathan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease
- (2018) Yasunori Suematsu et al. JOURNAL OF CARDIAC FAILURE
- Mechanisms of physiological and pathological cardiac hypertrophy
- (2018) Michinari Nakamura et al. Nature Reviews Cardiology
- TGF-β1 Signaling and Tissue Fibrosis
- (2017) Kevin K. Kim et al. Cold Spring Harbor Perspectives in Biology
- Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction
- (2017) Erik B. Schelbert et al. JAMA Cardiology
- Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction
- (2016) Sanjiv J. Shah et al. CIRCULATION
- Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure
- (2016) Benjamin French et al. JOURNAL OF CARDIAC FAILURE
- TGF-β: the master regulator of fibrosis
- (2016) Xiao-ming Meng et al. Nature Reviews Nephrology
- Heart failure with preserved ejection fraction: uncertainties and dilemmas
- (2015) Roberto Ferrari et al. EUROPEAN JOURNAL OF HEART FAILURE
- Cardiac Imaging to Evaluate Left Ventricular Diastolic Function
- (2015) Frank A. Flachskampf et al. JACC-Cardiovascular Imaging
- PARP-Inhibitor Treatment Prevents Hypertension Induced Cardiac Remodeling by Favorable Modulation of Heat Shock Proteins, Akt-1/GSK-3β and Several PKC Isoforms
- (2014) Laszlo Deres et al. PLoS One
- A Novel Paradigm for Heart Failure With Preserved Ejection Fraction
- (2013) Walter J. Paulus et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Myofibroblast-mediated mechanisms of pathological remodelling of the heart
- (2012) Karl T. Weber et al. Nature Reviews Cardiology
- Constitutive glycogen synthase kinase-3α/β activity protects against chronic β-adrenergic remodelling of the heart
- (2010) Ian G. Webb et al. CARDIOVASCULAR RESEARCH
- Celecoxib modulates hypertrophic signalling and prevents load-induced cardiac dysfunction
- (2008) Claudius Jacobshagen et al. EUROPEAN JOURNAL OF HEART FAILURE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started